THERAPY OF PANCREATIC CARCINOMAS (PACA) TRANSPLANTATION TUMORS WITH ANTI-CA19-9-I-131 AS WELL AS ANTI-CA19-9+ANTI-CEA-I-131

被引：0
|
作者：
KLAPDOR, R [1 ]
LANDER, S [1 ]
BAHLO, M [1 ]
MONTZ, R [1 ]
机构：
[1] UNIV HAMBURG,MED KERNKLIN & POLIKLIN,NUKL MED ABT,D-2000 HAMBURG 13,FED REP GER
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 1986年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [21] The impact of CA 19-9 on survival in patients with clinical stage I pancreatic cancer
    Melucci, Alexa D.
    Chacon, Alexander C.
    Burchard, Paul R.
    Ullman, Nicholas A.
    Tsagkalidis, Vasleios
    Casabianca, Anthony S.
    Reitz, Alexandra
    Swift, David A.
    Goyal, Subir
    Switchenko, Jeffrey M.
    Carpizo, Darren R.
    Shah, Mihir Maheshkumar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [22] Impact of CA 19-9 on Survival in Patients with Clinical Stage I Pancreatic Cancer
    Melucci, Alexa D.
    Chacon, Alexander C.
    Burchard, Paul R.
    Ullman, Nicholas A.
    Tsagkalidis, Vasleios
    Casabianca, Anthony S.
    Reitz, Alexandra C.
    Swift, David A.
    Goyal, Subir
    Switchenko, Jeffrey
    Carpizo, Darren R.
    Shah, Mihir M.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 445 - 446
  • [23] A Mutated Anti-CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts
    Matthew M. Rochefort
    Mark D. Girgis
    Scott M. Knowles
    Jacob S. Ankeny
    Felix Salazar
    Anna M. Wu
    James S. Tomlinson
    Molecular Imaging and Biology, 2014, 16 : 721 - 729
  • [24] SIGNIFICANCE OF IMMUNOSCINTIGRAPHY (IS) USING SPECT AND I-131 LABELED MONOCLONAL-ANTIBODIES (MAB) TO CEA/CA 19-9 IN THE FOLLOW-UP OF COLORECTAL-CANCER
    LEINSINGER, G
    SCHEIDHAUER, K
    DENECKE, H
    KRAGH, P
    HAAG, A
    MOSER, E
    KIRSCH, CM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1988, 14 (5-6): : 223 - 223
  • [25] A Mutated Anti-CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts
    Rochefort, Matthew M.
    Girgis, Mark D.
    Knowles, Scott M.
    Ankeny, Jacob S.
    Salazar, Felix
    Wu, Anna M.
    Tomlinson, James S.
    MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (05) : 721 - 729
  • [26] Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody
    Hombach, A
    Tillmann, T
    Jensen, M
    Heuser, C
    Sircar, R
    Diehl, V
    Kruis, W
    Pohl, C
    JOURNAL OF IMMUNOTHERAPY, 1997, 20 (05): : 325 - 333
  • [27] Prognostic values of CEA, CA19-9, and CA72-4 in patients with stages I-III colorectal cancer
    Wu, Tiantong
    Mo, Yali
    Wu, Chengtang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (07): : 1608 - 1614
  • [28] Imaging of Primary and Metastatic Pancreatic Cancer Using a Fluorophore-Conjugated Anti-CA19-9 Antibody for Surgical Navigation
    Michele McElroy
    Sharmeela Kaushal
    George A. Luiken
    Mark A. Talamini
    A. R. Moossa
    Robert M. Hoffman
    Michael Bouvet
    World Journal of Surgery, 2008, 32 : 1057 - 1066
  • [29] Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation
    McElroy, Michele
    Kaushal, Sharmeela
    Luiken, George A.
    Talamini, Mark A.
    Moossa, A. R.
    Hoffman, Robert M.
    Bouvet, Michael
    WORLD JOURNAL OF SURGERY, 2008, 32 (06) : 1057 - 1066
  • [30] A phase I/II trial of radioimmunotherapy with 131Iodine labelled A5B7 anti-CEA antibody (131I-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas
    Gaya, A. M.
    Violet, J.
    Dancey, G.
    Green, A.
    Stratford, M.
    Sharma, S.
    Owen, K.
    Padhani, A.
    Rustin, G. J.
    Begent, R. H.
    Meyer, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345